{"nctId":"NCT03897439","briefTitle":"Individualizing Pharmacotherapy for African American Smokers","startDateStruct":{"date":"2019-05-01","type":"ACTUAL"},"conditions":["Smoking Cessation"],"count":392,"armGroups":[{"label":"Usual Care (UC)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nicotine patch"]},{"label":"Optimized Care (OPT)","type":"EXPERIMENTAL","interventionNames":["Drug: Nicotine patch","Drug: Varenicline Tartrate","Drug: Bupropion"]}],"interventions":[{"name":"Nicotine patch","otherNames":["Nicoderm"]},{"name":"Varenicline Tartrate","otherNames":["Chantix"]},{"name":"Bupropion","otherNames":["Zyban","Wellbutrin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-Hispanic African American\n* â‰¥ 18 years of age\n* Smoke 5-30 cigarettes per day (CPD)\n* Daily cigarette smoker\n* Smoked at current rate for \\> 6 months\n* Verified smoker (CO \\> 5 ppm)\n* Functioning telephone\n* Interested in quitting smoking\n* Willing to take NP, VAR , and/or BUP+NP for 18 weeks and complete all study visits\n\nExclusion Criteria:\n\n* Use of non-cigarette tobacco products in past 30 days\n* Medical contraindications to NP, BUP, or VAR: unstable cardiac condition (e.g., unstable angina or AMI) cardiac event, or stroke in the past 4 weeks; renal impairment; medications contraindicated ; history of clinically significant allergic reactions; history of epilepsy, seizure, head trauma, psychosis, bipolar disorder, eating disorder; unstable panic disorder or depression; active suicidal ideation; treatment for alcohol or drug dependence in the past year\n* Use of pharmacotherapy in the month prior to enrollment\n* Pregnant, contemplating getting pregnant, or breastfeeding\n* Unstable housing (e.g., street, shelter)\n* Plans to move from Kansas City during the treatment and follow-up phase\n* Another household member enrolled in the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Biochemically Verified Smoking Abstinence at Week 12","description":"Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 12 visit. This will evaluate the short-term efficacy of optimized pharmacotherapy for smoking cessation in African American smokers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biochemically Verified Smoking Abstinence at Week 18","description":"Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 18 visit. This will evaluate the end-of-treatment efficacy of optimized pharmacotherapy for smoking cessation in African American smokers","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Biochemically Verified Smoking Abstinence at Week 26","description":"Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 26 visit. This will evaluate the long-term efficacy of optimized pharmacotherapy for smoking cessation in African American smokers","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":196},"commonTop":["Redness/swelling/rash on the skin","Nausea or Vomiting","Sleeping Problems"]}}}